Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Northwestern University
With
Progenics Pharmaceuticals, Inc.
Age
18–89
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must have a biopsy-proven diagnosis of high risk, very high risk, or locally advanced prostate cancer
Patients must have a diagnosis of high risk, very high risk, or locally advanced prostate cancer per NCCN Guidelines (T3-T4 disease)
Patients are healthy enough to be deemed surgical candidates with an ECOG performance status of 0-2
Patients must be age ≥ 18 years
Patients must agree to use adequate contraception (e.g. barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of the imaging
Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
You may not be if
Patients who have contraindications to MRI (i.e. pacemakers, aneurysm clips or shaped fragments)
Patients who are claustrophobic will be required to take an anti-anxiety medication prescribed by their physician one hour prior to the scan
Patients may not be receiving any other treatments or investigational agents
Patients not interested in pursuing surgical intervention for their disease (i.e. refusing treatment or requesting radiation oncology referral)
Patients who have received androgen deprivation therapy or prior surgery for prostate cancer
Patients who report taking multivitamins and/or folate supplements on the day of the scan
Clareo Health | PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
